Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

8.160 -0.110 (-1.33%)
Streaming Delayed Price Updated: 10:58 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 210,797
Open 8.250
Bid (Size) 8.160 (7)
Ask (Size) 8.170 (10)
Prev. Close 8.270
Today's Range 8.139 - 8.250
52wk Range 3.960 - 11.46
Shares Outstanding 358,808,755
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value
The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden. 
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
+4.88%
+4.88%
1 Month
+34.43%
+34.43%
3 Month
+14.77%
+14.77%
6 Month
-20.00%
-20.00%
1 Year
+0.25%
+0.25%

More News

Read More
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Via Investor's Business Daily
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
Via ACCESSWIRE
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
Bank Of Canada Cuts Rates Again As Inflation, Labor Market Cool: Canadian Stocks Rebound, Loonie Strengthens
Via Benzinga
Topics Economy
Exposures Interest Rates
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Via Benzinga
BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Bausch health Shares Are Falling Today
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Stocks Plummet After Tech Earnings, Manufacturing Data
Via Talk Markets
Topics Stocks
Exposures US Equities
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Via Benzinga
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.